Tango Therapeutics’ vopimetostat plus Revolution Medicines’ daraxonrasib combination produced durable response signals in an early-stage study of metastatic pancreatic ductal adenocarcinoma with MTAP deletion and RAS mutations, according to newly shared clinical readouts. Shares rose following the report of response rate and durability stronger than expected for a small trial population.